Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Melanoma 36Carcinoma, Renal Cell 16Prostatic Neoplasms 10Neoplasm Metastasis 10Leukemia, Myeloid, Acute 9Carcinoma, Non-Small-Cell Lung 9Uveal Melanoma 8Myelodysplastic Syndromes 8Leukemia, Lymphocytic, Chronic, B-Cell 7Clear-cell metastatic renal cell carcinoma 7Lymphoma, Non-Hodgkin 6Lung Neoplasms 6Hematologic Neoplasms 6Triple Negative Breast Neoplasms 5Sarcoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Ovarian Neoplasms 5Multiple Myeloma 5Hodgkin Disease 5Breast Neoplasms 5Brain Neoplasms 5Uterine Cervical Neoplasms 4Pancreatic Neoplasms 4Lymphoma, Follicular 4Histiocytoma, Malignant Fibrous 4Gastrointestinal Stromal Tumors 4Burkitt Lymphoma 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3

Interventions

Ipilimumab 17tremelimumab 9Nivolumab 9durvalumab 8pembrolizumab 6Paclitaxel 5Carboplatin 4Capecitabine 4Bevacizumab 4lenvatinib 3spartalizumab 2balstilimab 2Radiotherapy 2Radiation 2Pemetrexed 2Oxaliplatin 2Doxorubicin 2Docetaxel 2Cisplatin 2CTLA-4 Antigen 2Blood Specimen Collection 2trastuzumab deruxtecan 1tilsotolimod 1tebentafusp 1relatlimab 1poly ICLC 1osimertinib 1folfirinox 1eribulin 1envafolimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Diabetes Mellitus, Insulin-Dependent, 12 × CTLA-4 Antigen × Clear all
NCT03182816 2017-06-09

CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor

Shanghai Cell Therapy Research Institute

Phase 1/2 Unknown
40 enrolled

Diabetes Mellitus, Insulin-Dependent, 12

NCT03179007 2017-06-07

CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor

Shanghai Cell Therapy Research Institute

Phase 1/2 Unknown
40 enrolled

Diabetes Mellitus, Insulin-Dependent, 12

Data powered by HemOnc (CC BY 4.0) Colophon âš¡